Evidence map›Paper›PMID 41143067›Full record

ArticleIJID regions2025

Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-up.

Kankanamalage Ridma Prasadini Karunathilake, Roshan Athula Kumara, Amali Karunathilaka, Abdul Wahid Mohamed Wazil, Nishantha Nanayakkara, Chandana Keerthi Bandara, Rajitha Asanga Abeysekera, Faseeha Noordeen, Indika Bandara Gawarammana, Champa Neelakanthi Ratnatunga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kankanamalage Ridma Prasadini KarunathilakeDepartment of Microbiology, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Roshan Athula KumaraDepartment of Microbiology, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Amali KarunathilakaDepartment of Microbiology, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Abdul Wahid Mohamed WazilNephrology Unit, National Hospital Kandy, Kandy, Sri Lanka.
Nishantha NanayakkaraNephrology Unit, National Hospital Kandy, Kandy, Sri Lanka.
Chandana Keerthi BandaraNephrology Unit, National Hospital Kandy, Kandy, Sri Lanka.
Rajitha Asanga AbeysekeraDepartment of Medicine, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Faseeha NoordeenDepartment of Microbiology, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Indika Bandara GawarammanaDepartment of Medicine, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.
Champa Neelakanthi RatnatungaDepartment of Microbiology, Faculty of Medicine, University of Peradeniya, Kandy, Sri Lanka.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to assess the immune response to a three-dose primary series of COVID-19 vaccination in kidney transplant recipients (KTRs), a population vulnerable to infection due to immunosuppression. Methods: This study was a longitudinal evaluation of neutralizing antibody (nAB) dynamics in 43 KTRs in a lower-middle-income setting receiving a three-dose homologous (messenger RNA [mRNA]-1273-mRNA-1273- BNT162b2) vaccination against COVID-19. Samples were obtained at time points (TP) as follows: TP0, pre-vaccination; TP1, 1-month post-first dose (mRNA-1273); TP2, 1-month post-second dose (mRNA-1273); TP3, 4 months post-second dose; TP4, 2 weeks post-third dose (BNT162b2); TP5, 5 months post-third dose; and TP6, 12 months post-third dose. Anti-SARS-CoV-2 nAB were detected using the Genscript cPass Results: Pre-vaccination serum analysis showed n = 7 KTRs had prior COVID-19 infection, classified as 'infected + vaccinated,' while others were 'vaccinated.' Both groups were similar in age (41.7 years vs 46.7 years, Conclusions: KTRs receiving a three-dose mRNA COVID-19 vaccine regimen maintained strong nAB levels at 1-year follow-up, with comparable antibody levels seen between KTRs with prior infection + vaccination and vaccination alone.

Indexed as

COVID-19Homologous vaccinationKidney TransplantLongitudinal Follow-upNeutralizing Antibody LevelsSeroconversion

Identifiers

PMID41143067
PMCPMC12549382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.